The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
Open accessAbstract
The targeted degradation of membrane proteins would afford an attractive and general strategy for treating various diseases that remain difficult with the current proteolysis-targeting chimera (PROTAC) methodology. We herein report a covalent nanobody-based PROTAC strategy, termed GlueTAC, for targeted membrane protein degradation with high specificity and efficiency. We first established a mass-spectrometry-based screening platform for the rapid development of a covalent nanobody (GlueBody) that allowed proximity-enabled cross-linking with surface antigens on cancer cells. By conjugation with a cell-penetrating peptide and a lysosomal-sorting sequence, the resulting GlueTAC chimera triggered the internalization and degradation of programmed death-ligand 1 (PD-L1), which provides a new avenue to target and degrade cell-surface proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Expanding and reprogramming the genetic code
Chin, J. W. (2017) · Nature · doi:10.1038/nature24031 · Cited by 737
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
Ahn, G., Banik, S. M., Miller, C. L., Riley, N. M., Cochran, J. R., & Bertozzi, C. R. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00770-1 · Cited by 619
Chen, Z.-L., Meng, J.-M., Cao, Y., Yin, J.-L., Fang, R.-Q., Fan, S.-B., Liu, C., Zeng, W.-F., Ding, Y.-H., Tan, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11337-z · Cited by 552
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
The intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
Schmitz, K. R., Bagchi, A., Roovers, R. C., van Bergen en Henegouwen, P. M. P., & Ferguson, K. M. (2013) · Structure · doi:10.1016/j.str.2013.05.008 · Cited by 250
Wang, N., Yang, B., Fu, C., Zhu, H., Zheng, F., Kobayashi, T., Liu, J., Li, S., Ma, C., Wang, P. G., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01087 · Cited by 245
Tamura, T., Ueda, T., Goto, T., Tsukidate, T., Shapira, Y., Nishikawa, Y., Fujisawa, A., & Hamachi, I. (2018) · Nature Communications · doi:10.1038/s41467-018-04343-0 · Cited by 242
Zolot, R. S., Basu, S., & Million, R. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3980 · Cited by 227
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 226
Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes
Miao, Y., Gao, Q., Mao, M., Zhang, C., Yang, L., Yang, Y., & Han, D. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102170 · Cited by 224
Self-citationDevelopment of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
Zhou, Y., Teng, P., Montgomery, N. T., Li, X., & Tang, W. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00146 · Cited by 221
Noninvasive imaging of immune responses
Rashidian, M., Keliher, E. J., Bilate, A. M., Duarte, J. N., Wojtkiewicz, G. R., Jacobsen, J. T., Cragnolini, J., Swee, L. K., Victora, G. D., Weissleder, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502609112 · Cited by 218
Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics
Li, Q., Chen, Q., Klauser, P. C., Li, M., Zheng, F., Wang, N., Li, X., Zhang, Q., Fu, X., Wang, Q., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.028 · Cited by 210
Adding an unnatural covalent bond to proteins through proximity-enhanced bioreactivity
Xiang, Z., Ren, H., Hu, Y., Coin, I., Wei, J., Cang, H., & Wang, L. (2013) · Nature Methods · doi:10.1038/nmeth.2595 · Cited by 157
Antibody–Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Neri, D. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0622 · Cited by 138
Chen, L., Cohen, J. D., Song, X., Zhao, A., Ye, Z., Feulner, C. J., Doonan, P. J., Somers, W., Lin, L., & Chen, P. R. (2016) · Scientific Reports · doi:10.1038/srep31899 · Cited by 129
Self-citationFang, T., Lu, X., Berger, D. R., Gmeiner, C., Cho, J., Schalek, R. L., Ploegh, H. L., & Lichtman, J. W. (2018) · Nature Methods · doi:10.1038/s41592-018-0177-x · Cited by 113
A Genetically Encoded aza-Michael Acceptor for Covalent Cross-Linking of Protein–Receptor Complexes
Furman, J. L., Kang, M., Choi, S., Cao, Y. J., Wold, E. D., Sun, S. B., Smider, V. V., Schultz, P. G., & Kim, C. H. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502851h · Cited by 112
Liu, J., Cao, L., Klauser, P. C., Cheng, R., Berdan, V. Y., Sun, W., Wang, N., Ghelichkhani, F., Yu, B., Rozovsky, S., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04259 · Cited by 105
Chen, X., Xiang, Z., Hu, Y., Lacey, V. K., Cang, H., & Wang, L. (2014) · ACS Chemical Biology · doi:10.1021/cb500453a · Cited by 101
A quantitative comparison of cytosolic delivery via different protein uptake systems
Verdurmen, W. P. R., Mazlami, M., & Plückthun, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-13469-y · Cited by 90
Protein labeling approach to improve lysosomal targeting and efficacy of antibody–drug conjugates
Han, Y., Da, Y., Yu, M., Cheng, Y., Wang, X., Xiong, J., Guo, G., Li, Y., Jiang, X., & Cai, X. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00265h · Cited by 36
Self-citationKemball, C. C., Fujinami, R. S., & Whitton, J. L. (2014) · ASM Press eBooks · doi:10.1128/9781555816698.ch19 · Cited by 12
Cited by
Targeted protein degradation: mechanisms, strategies and application
Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 951
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Self-citationThe Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Targeted protein modification as a paradigm shift in drug discovery
Amirian, R., Azadi Badrbani, M., Izadi, Z., Samadian, H., Bahrami, G., Sarvari, S., Abdolmaleki, S., Nabavi, S. M., Derakhshankhah, H., & Jaymand, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115765 · Cited by 18
Metadata
- Authors
- Zhang, H., Han, Y., Yang, Y., Lin, F., Li, K., Kong, L., Liu, H., Dang, Y., Lin, J., & Chen, P. R.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-01
- Volume
- 143
- Issue
- 40
- Pages
- 16377-16382
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W3172027657
- Cited by
- 292
- References
- 32
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.